Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Moleculin Biotech, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 24 | 26 | +2 |
| Shares | 2.86M | 3.02M | +163.8K (+5.7%) |
| Value | $8.57M | $5.61M | −$2.96M (−34.5%) |
New holders (7)
Institutions that held Moleculin Biotech, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 46,647 | $87.0K | 0.01% |
| Sigma Planning Corp | 43,000 | $80.0K | 0.00% |
| Renaissance Technologies LLC | 33,400 | $62.0K | 0.00% |
| Two Sigma Securities, LLC | 22,174 | $41.0K | 0.01% |
| Two Sigma Advisers, LP | 18,400 | $34.0K | 0.00% |
| Goldman Sachs Group Inc | 11,825 | $22.0K | 0.00% |
| CVA Family Office, LLC | 500 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Moleculin Biotech, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Truist Financial Corp | 29,167 | $88.0K |
| Raymond James & Associates | 14,175 | $43.0K |
| UBS Group AG | 1,403 | $4.00K |
| Global Retirement Partners, LLC | 221 | $1.00K |
| Tower Research Capital LLC (TRC) | 40 | $0 |